ABOUT RIVOCERANIB
Rivoceranib is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), the primary pathway for tumor angiogenesis.1
VEGFR-2 inhibition is a clinically validated approach to limit tumor growth and disease progression.1
Rivoceranib was the first small-molecule tyrosine kinase inhibitor (TKI) approved as a gastric cancer treatment option under the name apatinib in China in December 2014. Apatinib is currently marketed in China for advanced gastric cancer by Jiangsu Hengrui Medicine Co., Ltd., under the brand name Aitan®.2
Today, rivoceranib has been studied in more than 6,000 patients worldwide and was well tolerated in clinical trials with a comparable safety profile to other TKIs.2,3
Elevar Therapeutics holds the global rights (excluding China) and has partnered for the development and marketing of rivoceranib with HLB-LS in South Korea.2